Nurix Therapeutics, Inc.
NRIX
$15.96
-$0.32-1.97%
NASDAQ
| 02/28/2026 | 11/30/2025 | 08/31/2025 | 05/31/2025 | 02/28/2025 | |
|---|---|---|---|---|---|
| Revenue | 71.78M | 83.98M | 83.69M | 88.38M | 56.42M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 71.78M | 83.98M | 83.69M | 88.38M | 56.42M |
| Cost of Revenue | 331.38M | 316.90M | 301.10M | 270.46M | 241.29M |
| Gross Profit | -259.60M | -232.92M | -217.42M | -182.08M | -184.87M |
| SG&A Expenses | 55.70M | 52.74M | 49.81M | 48.37M | 45.80M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 387.08M | 369.65M | 350.92M | 318.84M | 287.09M |
| Operating Income | -315.30M | -285.67M | -267.23M | -230.45M | -230.67M |
| Income Before Tax | -294.52M | -263.70M | -244.02M | -206.47M | -208.22M |
| Income Tax Expenses | 760.00K | 760.00K | 768.00K | 850.00K | 180.00K |
| Earnings from Continuing Operations | -295.28 | -264.46 | -244.79 | -207.32 | -208.40 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -295.28M | -264.46M | -244.79M | -207.32M | -208.40M |
| EBIT | -315.30M | -285.67M | -267.23M | -230.45M | -230.67M |
| EBITDA | -307.31M | -277.53M | -259.36M | -222.22M | -222.35M |
| EPS Basic | -3.16 | -3.04 | -2.97 | -2.61 | -2.81 |
| Normalized Basic EPS | -1.97 | -1.90 | -1.85 | -1.63 | -1.75 |
| EPS Diluted | -3.16 | -3.04 | -2.97 | -2.61 | -2.81 |
| Normalized Diluted EPS | -1.97 | -1.90 | -1.85 | -1.63 | -1.75 |
| Average Basic Shares Outstanding | 373.20M | 346.69M | 330.01M | 318.63M | 297.13M |
| Average Diluted Shares Outstanding | 373.20M | 346.69M | 330.01M | 318.63M | 297.13M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |